Cancer drug study extends treatment for responding patients
NCT ID NCT06506955
Summary
This study allows cancer patients who were already receiving futibatinib in a previous Taiho-sponsored trial to continue taking the medication if they're benefiting from it. The main purpose is to monitor the long-term safety of continued futibatinib treatment. Only patients who haven't met discontinuation criteria from their original study and are still showing benefit can participate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centro Integral Oncologico
Madrid, 28050, Spain
-
Hospital Universitari, Vall d'Hebron
Barcelona, 8035, Spain
-
Institut De Cancerologie Strasbourg
Strasbourg, 67033, France
-
Institut Paoli-Calmettes
Marseille, 13009, France
-
Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
Sarah Cannon Research Institute UK
London, W1G 6AD, United Kingdom
-
Severance Hospital
Seoul, 3722, South Korea
-
University College London Hospitals NHS Foundation Trust
London, W1T 7HA, United Kingdom
-
University of California, San Francisco (UCSF)
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.